M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT03840915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
Study identification
- NCT ID
- NCT03840915
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
- Nab-paclitaxel Drug
- Gemcitabine Drug
- Docetaxel Drug
- M7824 Drug
- Bintrafusp alfa Drug
- Paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2019
- Primary completion
- Jul 28, 2022
- Completion
- Jul 28, 2022
- Last update posted
- Aug 20, 2023
2019 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Care Research Group Inc - Edinger Medical Group, Inc. | Fountain Valley | California | 92708 | — |
| California Cancer Associates for Research & Excellence, Inc. | San Marcos | California | 92069 | — |
| Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Baptist Health Lexington Oncology Associates | Lexington | Kentucky | 40503 | — |
| University of Maryland - DUPLICATE/Pediatric Surgery | Baltimore | Maryland | 21201 | — |
| RCCA MD LLC - Bethesda | Bethesda | Maryland | 20817 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-8805 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03840915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03840915 live on ClinicalTrials.gov.